The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 1, 2009, Pages 124-129

  Knedla, A ^a   Riepl, B ^b   Lefevre S ^a   Kistella, S ^a   Grifka, J ^b   Straub, R H ^b   Gay, S ^c   Scholmerich J ^b   Muller Ladner U ^a   Neumann, E ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE GRAFT; CELL CULTURE; CELL ISOLATION; CELL PROTECTION; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCID MOUSE; SYNOVIUM; THERAPY EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; CELLS, CULTURED; FEMALE; GENE THERAPY; INFUSION PUMPS, IMPLANTABLE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; MICE; MICE, SCID; MODELS, ANIMAL; TRANSDUCTION, GENETIC;

EID: 58349109249     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.086116     Document Type: Article

References (25)

1. Knedla A, Neumann E, Müller-Ladner U. Developments in the synovial biology field 2006. Arthritis Res Ther 2007; 9:209.
2. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000; 2:59-64.
3. Müller-Ladner U, Kriegsmann J, Gay RE, Gay S. Oncogenes in rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21:675-90.
4. Müller-Ladner U, Gay RE, Gay S. Molecular biology of cartilage and bone destruction. Curr Opin Rheumatol 1998; 10:212-9.
5. Müller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 19961; 149:1607-15.
6. Keyszer GM, Heer AH, Kriegsmann J, Geiler T, Trabandt A, Keysser M, et al. Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis Rheum 1995; 38:976-84.
7. Schett G, Zwerina J, Firestein G. The p38 mitogen activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008; 67:909-16.
8. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12:861-70.
9. Noureddini SC, Krendelshchikov A, Simonenko V, Hedley SJ, Douglas JT, Curiel DT, et al. Generation and selection of targeted adenoviruses embodying optimized vector properties. Virus Res 2006; 116:185-95.
10. Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007; 18:589-602.
11. Neumann E, Judex M, Kullmann F, Grifka J, Robbins P, Pap T, et al. Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene Ther 2002; 9:1508-19.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
13. Judex M, Neumann E, Fleck M, Pap T, Mountz JD, Gay RE, et al. "Inverse wrap": an improved implantation technique for virus-transduced synovial fibroblasts in the SCID mouse model for rheumatoid arthritis. Mod Rheumatol 2001; 11:145-50.
14. Müller-Ladner U, Roberts CR, Franklin BN, Gay RE, Robbins PD, Evans CH, et al. Human IL-1ra gene transfer into human synovial fibroblasts is chondroprotective. J Immunol 1997; 158:3492-8.
15. Müller-Ladner U, Evans CH, Franklin BN, Roberts CR, Gay RE, Robbins PD, et al. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum 1999; 42:490-7.
16. Kalden JR. How do the biologics fit into the current DMARD armamentarium? J Rheumatol 2001; 62:27-35.
17. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1ra Arthritis Study Group. Arthritis Rheum 1996; 39:1092-101.
18. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998: 41:2196-204.
19. Moreland LW, Margolies G, Heck LWJ, Saway A, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23:1849-55.
20. van den Berg WB, Joosten LA, Helsen M, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95:237-43.
21. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-8.
22. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40:249-60.
23. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006; 6:215-26.
24. Kurosaka D, Yoshida K, Yasuda J, Yasuda C, Noda K, Furuya K, et al. The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. Scand J Rheumatol 2007; 36:434-41.
25. Badlani N, Inoue A, Healey R, Coutts R, Amiel D. The protective effect of OP-1 on articular cartilage in the development of osteoarthritis. Osteoarthritis Cartilage 2008; 16:600-6.